Tag Archives: VRX

Top 10 Canadian Stocks To Buy For 2018

Investment company Forte Capital Llc buys Cummins Inc, Canadian National Railway Co, Maxim Integrated Products Inc, iShares Core U.S. Aggregate Bond, Colgate-Palmolive Co, DowDuPont Inc, NVIDIA Corp, Raytheon Co, Facebook Inc, Phillips 66, sells Vanguard Small-Cap, iShares TIPS Bond, iShares Russell 1000 Growth, E.I. du Pont de Nemours, iShares 7-10 Year Treasury Bond ETF during the 3-months ended 2017-09-30, according to the most recent filings of the investment company, Forte Capital Llc . As of 2017-09-30, Forte Capital Llc owns 158 stocks with a total value of $311 million. These are the details of the buys and sells.

New Purchases: CMI, CNI, MXIM, DWDP, NVDA, RTN, IPGP, PSX, SCHA, NOVT, Added Positions: BIV, BSV, AGG, CL, VOE, FB, IWP, MO, DLR, SIX, Reduced Positions: RPG, VBR, VBK, IWF, MA, GILD, CSCO, IEF, MKTX, LOW, Sold Out: VB, TIP, DD, LUK, PNRA,

For the details of FORTE CAPITAL LLC ‘s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=FORTE+CAPITAL+LLC+

Top 10 Canadian Stocks To Buy For 2018: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

Top 10 Canadian Stocks To Buy For 2018: Talisman Energy Inc.(TLM)

Advisors’ Opinion:

  • [By Jayson Derrick]

    On the other hand, the analysts are Underweight on Eni SpA (ADR) (NYSE: E), Repsol Oil & Gas Canada Inc (USA) (NYSE: TLM) and OMV AG given their asset bases, which offer an inferior risk to reward profile and limited differentiation in cost reductions.

Top 10 Canadian Stocks To Buy For 2018: Patni Computer Systems Limited(PTI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Proteostasis Therapeutics Inc (NASDAQ: PTI) shares shot up 162 percent to $6.16 after the company disclosed 'positive' PTI-428 data with statistical significance.

  • [By William Romov]

    Before we show you our pick, here are the top 10 penny stocks to watch this week

    Penny Stock Current Share Price Nov. 27-Dec. 1 Gain (as of Dec. 1)
    Pyxis Tankers Inc. (Nasdaq: PXS) $4.10 122.83%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.28 68.42%
    Cerecor Inc. (Nasdaq: CERC) $1.74 47.46%
    Proteostasis Therapeutics Inc. (Nasdaq: PTI) $2.52 37.71%
    UT Starcom Holdings Corp. (Nasdaq: UTSI) $5.20 37.20%
    WMIH Corp. (Nasdaq: WMIH) $0.96 33.46%
    PhaseRx Inc. (Nasdaq: PZRX) $0.90 30.29%
    Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $2.04 29.94%
    EV Energy Partners LP (Nasdaq: EVEP) $0.86 27.76%
    Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) $4.40 25.71%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, its completely free

Top 10 Canadian Stocks To Buy For 2018: NRG Energy Inc.(NRG)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was NRG Energy, Inc. (NYSE: NRG) which rose over 5% to $22.20. The stocks 52-week range is $9.84 to $23.36. Volume was over 35 million compared to its average volume of 5.8 million.

  • [By Ben Levisohn]

    NRG Energy (NRG) has gained 2.1% to $18.49 after getting raise to Buy from Neutral at Goldman Sachs.

    Skechers USA (SKX) has tumbled 5.4% to$28.35 after getting cut to Negative from Positive at Susquehanna.

  • [By Ben Levisohn]

    NRG Energy (NRG) soared to the top of the S&P 500 today.

    Getty Images

    NRG Energygained 4.5% to $12.85 today, while the S&P 500 advanced 0.2% to 2,262.53.

    In a note released on Dec. 15, Morgan Stanley’sStephen Byrd and team summarized the reasoning behind their overweight rating on NRG:

    NRG Energy (NRG, Overweight, $21 PT) FCF/Equity yield of ~35% and balanced upside from diversified market exposure, higher PJM capacity prices, fleet optimization, and debt reduction. NRG’s generation plus retail matching strategy is an underappreciated source of value, and provides stable cash flow despite current depressed power prices in Texas.

    NRG Energy’s market capitalization rose to $4.1 billion today from $3.8 billion yesterday. It reported a net loss of $6.4 billion on sales of $15 billion in 2015.

    NRG Energy was the Biggest Loser on Nov. 10, and the Hot Stock on Nov. 4.

  • [By Lisa Levin]

    Non-cyclical consumer goods & services sector was the top gainer in the US market on Wednesday. Top gainers in the sector included Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG), Companhia Paranaense de Energia (ADR) (NYSE: ELP), and NRG Energy Inc (NYSE: NRG).

  • [By Lisa Levin]

    In trading on Wednesday, utilities shares fell 0.25 percent. Meanwhile, top losers in the sector included NRG Energy Inc (NYSE: NRG), down 3 percent, and Entergy Corporation (NYSE: ETR) down 1 percent.

Top 10 Canadian Stocks To Buy For 2018: Canadian National Railway Company(CNI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Canadian National Railway (USA) (NYSE: CNI) is estimated to post its quarterly earnings at $0.92 per share on revenue of $3.08 billion.

    Container Store Group Inc (NYSE: TCS) is expected to post its quarterly earnings at $0.21 per share on revenue of $230.53 million.

  • [By Brett Hershman]

    The Swiss bank said it was raising first-quarter estimates on four of the six rails it covers, with updated estimates above consensus on Canadian National Railway (USA) (NYSE: CNI), CSX Corporation (NASDAQ: CSX) and Kansas City Southern (NYSE: KSU), which is seen to show upside against low expectations.

  • [By Paul Ausick]

    GE got some good news this past week with an order for 200 locomotives from Canadian National Railway Co. (NYSE: CNI). The locomotives will be built at GE’s plant in Fort Worth, Texas, and deliveries to the rail operator will begin next year. The balance of the locomotives will be delivered in 2019 and 2020.

Top 10 Canadian Stocks To Buy For 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 3.7% Tuesday to post a new 52-week low of $10.08 after closing Monday at $10.47. The stock’s 52-week high is $38.50. Volume of about 14 million shares was about 30% below the daily average of around 19 million. The company said on Monday that CEO Joseph Papa took home total compensation of nearly $63 million as the stock was losing 62% of its value. The numbers speak for themselves.

  • [By Chris Lange]

    Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares had an incredible gain on Tuesday after the company announced a licensing agreement with Valeant Pharmaceuticals International Inc. (NYSE: VRX). At one point in the day shares were up over 100%. According to the deal, Eyegate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the Eyegate II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.

  • [By Peter Graham]

    Controversialmid capspecialty pharmastockValeant Pharmaceuticals International (NYSE: VRX) reportedQ1 2017 earnings before the market opened this morning with shares soaring in premarket trading. Valeant Pharmaceuticalshad beenwidelycriticized for pioneering the highly lucrative business model of acquiring pharmaceutical companies or their drugs, incorporating these drugs intoits sales and supply chain and thenjacking up the prices of these medications to levels contemporaneous with similar pharmaceutical products. In February 2016,the Companydisclosed that it was under investigation by the SEC and by the U.S. Attorney’s Offices for the Southern District of New York and then came under further criticism from politicians.

  • [By Ashley Moore]

    This next company to short continues to make headlines for its purportedly illegal business practices…

    Stocks to Short No. 2: Valeant Pharmaceuticals International Inc. (NYSE: VRX)

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) is known for its questionable business practices. The company is notorious for buying smaller pharmaceutical companies (financed with debt), firing the staff of the newly acquired company, and dramatically raising prices of the new drugs at its disposal.

  • [By Virendra Singh Chauhan]

    Nvidia corporation stock shook off the bad performance from the last week, with a nearly 3% gain in the first trading session of this week. If you are wondering whether or not NVIDIA stock has turned the corner, a recent tweet from NVIDIA bear Andrew Left offers some answers. In late December, Citron’s Andrew Left issued a bearish NVDA call, calling a $90 bottom on the stock. Well, the famed short seller of Valeant (NYSE:VRX) fame, recently disclosed that he had covered its short position on NVIDIA. Given that Citron had originally called for a $90 price target, it appears likely that Citron thinks NVDA stock has bottomed out $10 above its original target.

Top 10 Canadian Stocks To Buy For 2018: Transcananda Pipelines Ltd.(TRP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Energy infrastructure companies ONEOK (NYSE:OKE) and TransCanada (NYSE:TRP) are both emerging from the energy market downturn as stronger entities. Each made smart acquisitions, with TransCanada buying U.S. gas pipeline company Columbia Pipeline Group, while ONEOK is in the process of gobbling up its MLP,ONEOK Partners (NYSE:OKS). While these deals enhanced the growth profiles of both companies, TransCanada still stands out as the better buy for long-term income investors. Here’s why.

  • [By WWW.KIPLINGER.COM]

    Energy stocks were driven by a hefty dose of M&A during the third quarter. And that will drive returns for TransCanada Corporation (TRP) during the next one.

  • [By Matthew DiLallo]

    After a series of setbacks in its attempts to build new oil pipelines, Canadian pipeline giant TransCanada (NYSE:TRP) completed a transformation transaction to acquire U.S. natural gas pipeline company Columbia Pipeline Group for $13 billion, which includes the assumption of debt. The key to that deal was that it increased the combined company’s near-term project pipeline to 23 billion Canadian dollars, which supports TransCanada’s ability to increase its dividend by 8% to 10% annually through 2020. After completing that deal, TransCanada made a bid to acquire all of the outstanding units that it did not own of affiliated MLP Columbia Pipeline Partners (NYSE:CPPL) in a transaction valued at $915 million. These acquisitions solidified TransCanada’s natural gas pipeline growth ambitions, enabling it to diversify away from oil pipelines.

  • [By Ben Levisohn]

    In a number of articles recently, following the US recent revival and potential approval of the previously blocked Keystone XL pipeline, a number of estimates have been provided suggesting a pending boom for the US steel industry is on the horizon (and US steel stocks have reacted in kind). In fact, this optimism, we believe, peaked today when a report from one of our competitors was published claiming that, the keystone XL pipeline could increase line pipe demand by 14.7% for 2 years. The problem here, we believe, rests with the facts that: (a) TransCanada (TRP) has already taken, and paid for, the steel to build the Keystone XL pipeline (the steel currently sits in storage facilities in both Regina, Canada and Arkansas, United States), (b) neither US Steel (X; SELL), AK Steel, Steel Dynamics, or Nucor have the ability to make the specialized steel required for the miles of pipe associated with this project, to include both the thickness and pressure requirements, according to this article from Reuters, and (c) assuming some of the pipe does need replacement, this would likely come from international steel makers who are capable of producing the specialized steel (again, as highlighted in this Reuters article).

  • [By Paul Ausick]

    That includes pipeline companies like Kinder Morgan Inc. (NYSE: KMI), which already operates a pipeline transporting natural gas from Texas into Mexico, and master limited partnerships (MLPs) Energy Transfer Partners L.P. (NYSE: ETP) and TransCanada Corp. (NYSE: TRP), the company that has (so far) failed to get U.S. approval for its Keystone Pipeline expansion from Canada’s oil sands across the U.S. border.

Top 10 Canadian Stocks To Buy For 2018: Credit Suisse Group(CS)

Advisors’ Opinion:

  • [By Paul R. La Monica]

    European banks worse off than 2008? Lamensdorf is concerned about the exposure to bad loans (especially energy company debt) held by big banks such as Royal Bank of Scotland (RBS), Credit Suisse (CS) and Deutsche Bank (DB). He’s shorting all three.

  • [By David Zeiler]

    The federal government’s largesse isn’t restricted to U.S.-based companies, either. Foreign companies, including foreign banks, are also welcome. Credit Suisse Group AG (NYSE ADR: CS) got $225.1 billion, and UBS Group AG (NYSE: UBS) got $249.1 billion.

  • [By Money Morning News Team]

    That’s why Krauth predicts the price of gold will hit $1,400 by the end of the year. Many analysts from banks likeCredit SuisseGroup AG (NYSE ADR: CS) even see gold going as high as $1,500.

  • [By Wayne Duggan] Related DB Deutsche Bank In The Tank Mike Khouw Sees Unusual Options Activity In Deutsche Bank 33 Large Banks On The Federal Reserve's Radar In 2016 (Seeking Alpha)
    Related CS Earnings Scheduled For February 4, 2016 Blockchain Moves Forward In The Financial Industry Credit Suisse Group AG (CS) Tidjane Thiam on Q4 2015 Results – Earnings Call Transcript (Seeking Alpha)

    The latest credit default swap (CDS) data from BMO Capital Markets indicate a number of investors are growing increasingly concerned about the one-year outlook for capital markets. In a new report, analyst Mark Steele discussed the recent surge in one-year CDS activity, and what it means for the market.

  • [By Diane Alter]

    The head underwriters for the ZTO IPO are Morgan Stanley (NYSE: MS) and Goldman Sachs Group Inc. (NYSE: GS). Also working on the deal are China Renaissance, Citigroup Inc. (NYSE: C), Credit Suisse Group AG (NYSE ADR: CS), and JPMorgan Chase & Co. (NYSE: JPM).

Top 10 Canadian Stocks To Buy For 2018: Prestige Brand Holdings Inc.(PBH)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Castor believes the cash has disappeared into working capital, which has grown from 23% to more than 50% since 2008. Comparable company PrestigeBrand (PBH) uses 11%; Unilever(UL) and Colgate-Palmolive(CL) far less.

Top 10 Canadian Stocks To Buy For 2018: Safeway Inc.(SWY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:

  • [By Peter Graham]

    A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:

Top Canadian Stocks To Invest In 2018

Canadian Cannabis Market Is Set To Explode

Public support for recreational cannabis is at an all-time high. This support will lead to the passage of legislation legalizing recreational cannabis across all of Canada. Deloitte estimates the size of the Canadian legal cannabis market at $8 billion.

Cannabis Will Be In Short Supply

Demand for cannabis in Canada, both recreational and medical, is expected to top 1.32 million pounds. Currently, the entire industry produces roughly 20,000 pounds annually. There is around 1 million pounds of annual cannabis production that needs to be accounted for.

In order to meet this growing demand, Abcann Global (OTCQB:ABCCF) is increasing production capacity at a rapid pace. While its current facilities total only 40,000 sq. feet of growing space, multiple new facilities are under construction that will boost total growing space to over 200,000 sq feet. The company is in the process of developing the land for a future facility with 1.2 million square feet of growing space.

Top Canadian Stocks To Invest In 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) sawits shares hit a multiyear low this past week. There was hope for a turnaround when Joe Papa took over as chief executive officer,but it seems that littlehas gone his way, especially after the company reported earnings early this week. Some analysts took this opportunity to reevaluate their stance on the stock. Although this might be a buy for some, the returns look to be getting smaller.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 2.4% Monday to post a new 52-week low of $8.31 after closing Friday at $8.51. The stock’s 52-week high is $38.50. Volume of around 13.5 million shares was about 65% below the daily average of around 18.8 million. The company had no specific news, and shares are on track to add about 1.5% by the closing bell.

  • [By Stark Merrifield]

    Bill Ackman: Fifty-year-old Ackmans career began in 1992 when he and fellow Harvard graduate David P. Berkowtiz founded the investment firm Gotham Partners. The firms high-profile bid for Rockefeller Center in New York caused investors to flock to the firm, growing it to $500 million in assets. Then in 2004, with $54 million in personal funding, Ackman started Pershing Square Capital Management. Through Pershing, Ackman bought significant shares in companies like Wendys Co. (Nasdaq: WEN), Target Corp. (NYSE: TGT), Chipotle Mexican Grill Inc. (NYSE: CMG), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). Today, Ackman is worth $1.4 billion and is No. 256 on the Forbes 400.

  • [By Ben Levisohn]

    If it feels like it’s been all Valeant Pharmaceuticals International (VRX) today, I get it, and I promise this will be my last post on the company today. But really, how often do we get to see a fund manager acknowledge a spectacular mistake in such publicfashion?

    Photo: Andrew Harrer/Bloomberg

    As if it weren’t obvious yet, Ackman’s exit is bad news for the stock.Yes, some analysts have tried to focus on other issues that could be positive, but, really, as long as Ackman was around, you knew someone big had Valeant’s back. And now he’s gone. We at Barron’s were never too enthusiastic about Valeant–Vito Racanelliwrote bearishly on the company 2014–or Ackman’s involvement. But it he was your reason to be in Valeant, well consider what Wells Fargo analyst David Maris has to say:

    …we believe investors will take Pershing Squares exit as a reflection that 1) the outlook is negative; 2) the potential for meaningful near-term asset sales is unlikely; 3) the legal proceedings/investigations may have greater risk than the Street is appreciating; 4) a turnaround will take longer than expected or is not possible; and 5) the debtholders have an advantaged position in the capital structure, and as such the equity holders are at their mercy, especially in a bankruptcy situation. We believe investors would consider this as a sign that the next several years may not represent a major turnaround for the company.

    Shares of Valeant have dropped 11% to$10.76 at 3:12 p.m.

Top Canadian Stocks To Invest In 2018: NRG Energy Inc.(NRG)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was NRG Energy, Inc. (NYSE: NRG) which rose over 5% to $22.20. The stocks 52-week range is $9.84 to $23.36. Volume was over 35 million compared to its average volume of 5.8 million.

  • [By Lisa Levin]

    Non-cyclical consumer goods & services sector was the top gainer in the US market on Wednesday. Top gainers in the sector included Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG), Companhia Paranaense de Energia (ADR) (NYSE: ELP), and NRG Energy Inc (NYSE: NRG).

  • [By Lisa Levin]

    In trading on Wednesday, utilities shares fell 0.25 percent. Meanwhile, top losers in the sector included NRG Energy Inc (NYSE: NRG), down 3 percent, and Entergy Corporation (NYSE: ETR) down 1 percent.

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

  • [By Rich Duprey]

    I ran a screen to identify the best-performing stocks from the S&P 500 in January. The top three performers during the month were Alcoa (NYSE:AA), CSX (NASDAQ:CSX), and NRG Energy (NYSE:NRG). Let’s see why they were the big standouts and whether they can keep it going.

Top Canadian Stocks To Invest In 2018: NEW GOLD INC.(NGD)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market lost ground on Monday, sending major market benchmarks lower by more than half a percentage point. The Dow lost its grip on the 20,000 mark in the wake of concerns about economic growth and new U.S. immigration policy, and some believe that the broader geopolitical climate could have a negative impact on global commerce that in turn could start affecting multinational corporations’ business prospects. In addition, bad news from some individual companies weighed on the markets, and Transocean (NYSE:RIG), Rite Aid (NYSE:RAD), and New Gold (NYSEMKT:NGD) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top Canadian Stocks To Invest In 2018: Encana Corporation(ECA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Vodafone Group (VOD) , Schlumberger (SLB) , Encana (ECA) , Arconic (ARNC) and AdvanSix (ASIX) .

    Cramer was bearish on U.S. Silica Holdings (SLCA) .

  • [By Paul Ausick]

    Encana Corp. (NYSE: ECA) is rated Buy with an unchanged price target of $16. The EPS estimate for 2017 was lowered from $0.42 to $0.34, and the 2018 estimate was also lowered, from $1.47 to $1.28. The shares ended the weekat $11.44, in a 52-week range of $4.90 to $13.85. The consensus 12-month price target is $14.95.

  • [By Money Morning News Team]

    Canada-based Encana Corp. (NYSE: ECA) was the eighth top oil company stock in 2016, with a 131% gain over the year. ECA and its subsidiaries focus on developing, exploring, producing, and marketing natural gas, liquefied natural gas, and oil in North America.

Hot Canadian Stocks To Buy Right Now

&l;p&g;&l;img class=&q;dam-image bloomberg size-large wp-image-41695972&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/41695972/960×0.jpg?fit=scale&q; data-height=&q;639&q; data-width=&q;960&q;&g; Jeff Sessions, U.S. attorney general, pauses after speaking during a House Judiciary Committee hearing in Washington, D.C., U.S., on Tuesday, Nov. 14, 2017. Andrew Harrer/Bloomberg

Marijuana stocks and exchange-traded funds were on fire in the New Year until Attorney General Jeff Sessions ignited a selloff Thursday upon announcing that he&a;rsquo;s retracting the Cole Memo, which lets individual states legalize cannabis without fear federal prosecutors will go after companies for trafficking.

Cannabics Pharmaceuticals, Medical Marijuana, United Cannabis, GreenGro Technologies, MassRoots and mCig crashed 25% to 30% each after flying high the two sessions prior as California&a;rsquo;s new marijuana laws went into effect. ETFMG Alternative Harvest ETF plunged 6%. Its Canadian counterpart, Horizons Marijuana Life Sciences Index ETF, dropped 8%. It trades over the counter in the U.S. under the ticker HMLSF.

Hot Canadian Stocks To Buy Right Now: Safeway Inc.(SWY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:

Hot Canadian Stocks To Buy Right Now: NRG Energy Inc.(NRG)

Advisors’ Opinion:

  • [By Rich Duprey]

    I ran a screen to identify the best-performing stocks from the S&P 500 in January. The top three performers during the month were Alcoa (NYSE:AA), CSX (NASDAQ:CSX), and NRG Energy (NYSE:NRG). Let’s see why they were the big standouts and whether they can keep it going.

  • [By Ben Levisohn]

    NRG Energy (NRG) soared to the top of the S&P 500 today.

    Getty Images

    NRG Energygained 4.5% to $12.85 today, while the S&P 500 advanced 0.2% to 2,262.53.

    In a note released on Dec. 15, Morgan Stanley’sStephen Byrd and team summarized the reasoning behind their overweight rating on NRG:

    NRG Energy (NRG, Overweight, $21 PT) FCF/Equity yield of ~35% and balanced upside from diversified market exposure, higher PJM capacity prices, fleet optimization, and debt reduction. NRG’s generation plus retail matching strategy is an underappreciated source of value, and provides stable cash flow despite current depressed power prices in Texas.

    NRG Energy’s market capitalization rose to $4.1 billion today from $3.8 billion yesterday. It reported a net loss of $6.4 billion on sales of $15 billion in 2015.

    NRG Energy was the Biggest Loser on Nov. 10, and the Hot Stock on Nov. 4.

  • [By Lisa Levin]

    In trading on Wednesday, utilities shares fell 0.25 percent. Meanwhile, top losers in the sector included NRG Energy Inc (NYSE: NRG), down 3 percent, and Entergy Corporation (NYSE: ETR) down 1 percent.

  • [By Craig Jones]

    Pete Najarian said that there was a big options activity in NRG Energy Inc (NYSE: NRG). Traders were aggressively buying the October 26 calls. Around 6,000 contracts were traded in the first half of the session and they were paying 65 cents for them. The trade breaks even at $26.65 or more than 11 percent above the current market price.

Hot Canadian Stocks To Buy Right Now: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Apache Corp. (NYSE: APA), Halliburton Co. (NYSE: HAL), Revlon Inc. (NYSE: REV), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and U.S. Steel Corp. (NYSE: X).

  • [By Keith Speights]

    It’s been a long time since Valeant Pharmaceuticals (NYSE:VRX) stock was in a legitimate uptrend. Despite the hiring of a new CEO last year to right the ship, Valeant’s share price has continued to fall.

  • [By Ben Levisohn]

    The gain is particularly striking considering the fact that Endo International dropped 73% in 2016, making it the worst performer in the S&P 500. Endo has been hit hard by concerns over drug pricing that has plagued the entire specialty pharmaceutical sector since Valeant Pharmaceuticals International’s (VRX) pricing strategy came to light last year.

  • [By Casey Wilson]

    As disgraceful as Mylan’s pricing strategy may be, this next pharmaceutical firm is hated even more – and makes our list for the second year in a row…

    Most-Hated Companies 2016 No. 1: Valeant Pharmaceuticals International Inc. (NYSE: VRX)

    The troubled pharmaceutical company is deeply loathed by both consumers and investors alike.

  • [By Kumar Abhishek]

    Shares of specialty pharma company Valeant Pharmaceuticals Intl Inc(NYSE:VRX)have tanked more than 20% in last two trading sessions, breaching the support from the 50 day SMA, after the Laval,Quebec-based company reported its Q4 and FY 2016 earnings on Tuesday, before the market opened. While the earnings itself were better than expected, the guidance for FY 2017 didn’t go down well with investors and wall street, earning the company multiple price target cuts. Valeant reported an adjusted profit of $1.26 a share against analysts’ estimateof $1.21. This was Valeant’s first beat in a long time. Even on the revenue front, the company reported better than expected results. Initially, the stock gained on the report of an earnings beat. However, once the guidance figures came in, the stock tanked. In our earnings preview of Valeant, we had said that the adjusted EBITDA guidance for 2017 will be the key driver of VRX stock after the earnings.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 0.1% Thursday to post a new 52-week low of $9.49 after closing Wednesday at $9.50. The stock’s 52-week high is $38.50. Volume of about 15 million shares was about 25% below the daily average of around 19 million. The company had no specific news.

Hot Canadian Stocks To Buy Right Now: Patni Computer Systems Limited(PTI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Proteostasis Therapeutics Inc (NASDAQ: PTI) shares shot up 162 percent to $6.16 after the company disclosed 'positive' PTI-428 data with statistical significance.

  • [By William Romov]

    Before we show you our pick, here are the top 10 penny stocks to watch this week

    Penny Stock Current Share Price Nov. 27-Dec. 1 Gain (as of Dec. 1)
    Pyxis Tankers Inc. (Nasdaq: PXS) $4.10 122.83%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.28 68.42%
    Cerecor Inc. (Nasdaq: CERC) $1.74 47.46%
    Proteostasis Therapeutics Inc. (Nasdaq: PTI) $2.52 37.71%
    UT Starcom Holdings Corp. (Nasdaq: UTSI) $5.20 37.20%
    WMIH Corp. (Nasdaq: WMIH) $0.96 33.46%
    PhaseRx Inc. (Nasdaq: PZRX) $0.90 30.29%
    Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $2.04 29.94%
    EV Energy Partners LP (Nasdaq: EVEP) $0.86 27.76%
    Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) $4.40 25.71%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, its completely free

Hot Canadian Stocks To Buy Right Now: Plains All American Pipeline L.P.(PAA)

Advisors’ Opinion:

  • [By Dustin Parrett]

    We think Plains All American Pipeline L.P. (NYSE: PAA) is one of the best oil stocks to buy this year. In fact, we see a scenario where PAA stock could jump 20% in 2017.

  • [By Dustin Parrett]

    Plains All American Pipeline (NYSE: PAA) controls 4 million barrels of crude oil and natural gas a day.

    And with higher oil prices and fewer restrictions leading to more drilling, PAA’s pipelines will be in demand in 2017.

  • [By Matthew DiLallo]

    One of the largest projects is the Saddlehorn Pipeline, which Magellan is building with Plains All American Pipeline (NYSE:PAA) and Anadarko Petroleum (NYSE:APC). Both Plains All American Pipeline and Magellan own 40% of the project, which puts their total investment at $230 million apiece. They expect the project to be fully operational early next year, which is noteworthy given its robust first-year economics. Magellan estimates that it will earn eight times EBITDA on the capital deployed, or roughly $28.8 million in annual EBITDA apiece for Magellan and Plains All American Pipeline on their investment.

Hot Canadian Stocks To Buy Right Now: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

Best Canadian Stocks To Own For 2018

Toshiba’s disastrous foray into the U.S. nuclear business is coming to an end.

The Japanese conglomerate is selling Westinghouse, its beleaguered U.S. nuclear unit, for $4.6 billion to Canadian investment firm Brookfield Business Partners, the companies said.

“The decision to sell Westinghouse is good news for creditors, as well as our company,” Toshiba said Friday.

The collapse of Westinghouse cost Toshiba some $6.4 billion, forcing the storied Japanese company to admit its financial future was in peril.

The conglomerate has been offloading major assets in order to survive, including selling control of its highly regarded memory chip business to a group of investors that includes Apple (AAPL).

Toshiba (TOSBF) stock rose about 2% in Tokyo following the news of the Westinghouse deal.

The sale offers a fresh start for Westinghouse, which was forced into bankruptcy last year after suffering billions of dollars in losses from delays and cost overruns at nuclear plants under construction in Georgia and South Carolina.

Best Canadian Stocks To Own For 2018: Canadian National Railway Company(CNI)

Advisors’ Opinion:

  • [By Brett Hershman]

    The Swiss bank said it was raising first-quarter estimates on four of the six rails it covers, with updated estimates above consensus on Canadian National Railway (USA) (NYSE: CNI), CSX Corporation (NASDAQ: CSX) and Kansas City Southern (NYSE: KSU), which is seen to show upside against low expectations.

  • [By Paul Ausick]

    GE got some good news this past week with an order for 200 locomotives from Canadian National Railway Co. (NYSE: CNI). The locomotives will be built at GE’s plant in Fort Worth, Texas, and deliveries to the rail operator will begin next year. The balance of the locomotives will be delivered in 2019 and 2020.

  • [By Monica Gerson]

    Canadian National Railway (USA) (NYSE: CNI) is estimated to post its quarterly earnings at $0.92 per share on revenue of $3.08 billion.

    Container Store Group Inc (NYSE: TCS) is expected to post its quarterly earnings at $0.21 per share on revenue of $230.53 million.

Best Canadian Stocks To Own For 2018: Silver Wheaton Corp(SLW)

Advisors’ Opinion:

  • [By Rich Duprey]

    Silver Wheaton (NYSE:SLW), of course, is a streamer like Sandstorm and Franco, but it is the largest in the precious-metals industry, and arguably the best-known, because its business model came to define what streaming is. Although it is known primarily for its silver contracts, Silver Wheaton also has sizable gold production that makes it worth your attention.

Best Canadian Stocks To Own For 2018: Talisman Energy Inc.(TLM)

Advisors’ Opinion:

  • [By Jayson Derrick]

    On the other hand, the analysts are Underweight on Eni SpA (ADR) (NYSE: E), Repsol Oil & Gas Canada Inc (USA) (NYSE: TLM) and OMV AG given their asset bases, which offer an inferior risk to reward profile and limited differentiation in cost reductions.

Best Canadian Stocks To Own For 2018: Thor Industries Inc.(THO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Thor Industries, Inc. (NYSE: THO) shares were also up, gaining 13 percent to $154.01 after the company reported stronger-than-expected results for its first quarter on Monday.

  • [By Lisa Levin]

    Thor Industries, Inc. (NYSE: THO) shares were also up, gaining 11 percent to $151.76 after the company reported stronger-than-expected results for its first quarter on Monday.

  • [By Peter Graham]

    A long term performance chart shows shares of Winnebago Industriesalong withmid cap peers Thor Industries, Inc (NYSE: THO) and LCI Industries (NYSE: LCII) all giving a very similar performance:

  • [By Dan Caplinger]

    Finally, shares of Winnebago Industries dropped 6%. The maker of recreational vehicles has been under pressure ever since rival Thor Industries (NYSE:THO) reported its most recent quarterly results earlier this week, and Thor’s story led shareholders to sell off that stock. Yet although Winnebago is in the same business as Thor, some investors think that it could succeed where Thor failed, especially because the Winnebago brand name is much more valuable and has greater customer recognition that many of its competitors’ offerings. Winnebago will have its own chance to report its financial results later this month, and although many investors seem to be betting against the RV maker, others believe that Winnebago could easily make its competitive advantage against Thor and other manufacturers clear with a solid performance this quarter.

  • [By Dan Caplinger]

    Recreational vehicles have hit a stretch of popularity that the industry hasn’t seen since the 1970s, and Thor Industries (NYSE:THO) has found itself in the right place at the right time. The RV specialist has made every effort it can to boost its growth to take advantage of favorable conditions, both by ramping up its existing internal operations and by looking for strategic combinations like its recent acquisition of industry peer Jayco. Coming into Monday’s fiscal second-quarter financial report, Thor investors were looking for very strong growth, and even though the company largely delivered on that front, some concerns about the pace of further gains throughout the rest of the fiscal year weighed on Thor stock after the report.

  • [By Lisa Levin]

    Shares of Thor Industries, Inc. (NYSE: THO) got a boost, shooting up 14 percent to $102.70 as the company reported stronger-than-expected results for its first quarter on Monday.

Best Canadian Stocks To Own For 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 6.4% Wednesday to post a new 52-week low of $9.52 after closing Tuesday at $10.17. The stock’s 52-week high is $38.50. Volume of about 35 million shares was nearly double the daily average of around 19 million. The company is reportedly having trouble selling one of its division for what it deems an acceptable price.

  • [By Ben Levisohn]

    The gain is particularly striking considering the fact that Endo International dropped 73% in 2016, making it the worst performer in the S&P 500. Endo has been hit hard by concerns over drug pricing that has plagued the entire specialty pharmaceutical sector since Valeant Pharmaceuticals International’s (VRX) pricing strategy came to light last year.

  • [By Stark Merrifield]

    Bill Ackman: Fifty-year-old Ackmans career began in 1992 when he and fellow Harvard graduate David P. Berkowtiz founded the investment firm Gotham Partners. The firms high-profile bid for Rockefeller Center in New York caused investors to flock to the firm, growing it to $500 million in assets. Then in 2004, with $54 million in personal funding, Ackman started Pershing Square Capital Management. Through Pershing, Ackman bought significant shares in companies like Wendys Co. (Nasdaq: WEN), Target Corp. (NYSE: TGT), Chipotle Mexican Grill Inc. (NYSE: CMG), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). Today, Ackman is worth $1.4 billion and is No. 256 on the Forbes 400.

  • [By WWW.THESTREET.COM]

    “I am working on a new system where there will be competition in the drug industry,” he said shortly before 9:00 a.m. EST. Within an hour, shares of several Big Pharma companies, including Mylan (MYL) , Valeant Pharmaceuticals (VRX) and Allergan (AGN) , had sunk by several percentage points.

Top Canadian Stocks To Own For 2018

Cardtronics (NASDAQ:CATM) is the world’s largest owner and operator of ATMs, a secularly challenged industry that is being persistently eroded on several fronts; cash usage is being supplanted by the increasing adoption of non-cash payment options such as debit/credit cards, contactless and mobile payment technologies; financial transactions are also increasingly moving online due to the growth of e-commerce, online banking and the proliferation of mobile internet access.

As a result, in most developed countries, the ATM industry is in a state of chronic decline. This is evident in every major market that Cardtronics operates in:

The latest Federal Reserve Payments Study shows a -0.9% CAGR in cash withdrawal transactions between 2009 and 2012 (an updated Payments Study is due in December of this year) According to LINK, cash withdrawal transactions in the UK declined by a 1.37% CAGR from 2012 to 2015 According to the Canadian Banking Association, between 2010 and 2015, cash withdrawal transactions at bank-owned ATMs have declined at a 4.1% CAGR (despite an overall increase in the number of ATMs) In Australia, cash withdrawal transactions have declined at an ~7% CAGR over the last four years, according to CommSec.

Aggressive acquisition strategy masks lack of organic growth opportunities

Top Canadian Stocks To Own For 2018: Encana Corporation(ECA)

Advisors’ Opinion:

  • [By Money Morning News Team]

    Canada-based Encana Corp. (NYSE: ECA) was the eighth top oil company stock in 2016, with a 131% gain over the year. ECA and its subsidiaries focus on developing, exploring, producing, and marketing natural gas, liquefied natural gas, and oil in North America.

  • [By Paul Ausick]

    Encana Corp. (NYSE: ECA) is rated Buy with an unchanged price target of $16. The EPS estimate for 2017 was lowered from $0.42 to $0.34, and the 2018 estimate was also lowered, from $1.47 to $1.28. The shares ended the weekat $11.44, in a 52-week range of $4.90 to $13.85. The consensus 12-month price target is $14.95.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Vodafone Group (VOD) , Schlumberger (SLB) , Encana (ECA) , Arconic (ARNC) and AdvanSix (ASIX) .

    Cramer was bearish on U.S. Silica Holdings (SLCA) .

Top Canadian Stocks To Own For 2018: Talisman Energy Inc.(TLM)

Advisors’ Opinion:

  • [By Jayson Derrick]

    On the other hand, the analysts are Underweight on Eni SpA (ADR) (NYSE: E), Repsol Oil & Gas Canada Inc (USA) (NYSE: TLM) and OMV AG given their asset bases, which offer an inferior risk to reward profile and limited differentiation in cost reductions.

Top Canadian Stocks To Own For 2018: Canadian National Railway Company(CNI)

Advisors’ Opinion:

  • [By Brett Hershman]

    The Swiss bank said it was raising first-quarter estimates on four of the six rails it covers, with updated estimates above consensus on Canadian National Railway (USA) (NYSE: CNI), CSX Corporation (NASDAQ: CSX) and Kansas City Southern (NYSE: KSU), which is seen to show upside against low expectations.

  • [By Monica Gerson]

    Canadian National Railway (USA) (NYSE: CNI) is estimated to post its quarterly earnings at $0.92 per share on revenue of $3.08 billion.

    Container Store Group Inc (NYSE: TCS) is expected to post its quarterly earnings at $0.21 per share on revenue of $230.53 million.

  • [By Paul Ausick]

    GE got some good news this past week with an order for 200 locomotives from Canadian National Railway Co. (NYSE: CNI). The locomotives will be built at GE’s plant in Fort Worth, Texas, and deliveries to the rail operator will begin next year. The balance of the locomotives will be delivered in 2019 and 2020.

Top Canadian Stocks To Own For 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By WWW.KIPLINGER.COM]

    Theres been follow-up, too: Valeant Pharmaceuticals Intl Inc (VRX) had to face the Senate in April for aggressively hiking prices on its drugs. Now Mylan NV (MYL) is answering to the government soon after a story showed that EpiPen prices have rocketed 400% since 2008 with no significant improvements to the treatment. This scandal, too, is rocking biotechs including (Link]recommendation SPDR S&P Biotech ETF (XBI).

  • [By Stark Merrifield]

    Bill Ackman: Fifty-year-old Ackmans career began in 1992 when he and fellow Harvard graduate David P. Berkowtiz founded the investment firm Gotham Partners. The firms high-profile bid for Rockefeller Center in New York caused investors to flock to the firm, growing it to $500 million in assets. Then in 2004, with $54 million in personal funding, Ackman started Pershing Square Capital Management. Through Pershing, Ackman bought significant shares in companies like Wendys Co. (Nasdaq: WEN), Target Corp. (NYSE: TGT), Chipotle Mexican Grill Inc. (NYSE: CMG), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). Today, Ackman is worth $1.4 billion and is No. 256 on the Forbes 400.

  • [By Kumar Abhishek]

    Valeant Pharmaceuticals Intl Inc(NYSE:VRX) stock has been rallying going into this earningsseason. Valeant stock is up by more than 20% since the beginningof February. VRX stock is currently facing resistance from the100-day simple moving average trendline. The run in the stock has been driven by the FDA approval of “Saliq”, a drug marketed by Valeant to treat adults with moderate-to-severe plaque psoriasis, and the company’s asset sales plans. Valeant has announcedasset sales of more than $2.5 billion since the beginning of the year. These asset sales will help in paring down some portion of Valeant’s $30 billion debt which is holding down the stock.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 3.7% Tuesday to post a new 52-week low of $10.08 after closing Monday at $10.47. The stock’s 52-week high is $38.50. Volume of about 14 million shares was about 30% below the daily average of around 19 million. The company said on Monday that CEO Joseph Papa took home total compensation of nearly $63 million as the stock was losing 62% of its value. The numbers speak for themselves.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 6% Tuesday to post a new 52-week low of $8.92 after closing Monday at $9.48. The stock’s 52-week high is $38.50. Volume of around 20 million shares was about 12 times the daily average of around 1.7 million. The company had no specific news Tuesday.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 8.5% Tuesday, to post a new 52-week low of $11.36 after closing at $12.41 on Monday. The stock’s 52-week high is $70.43. Volume was about double the daily average of around 16.6 million shares. The company announced Monday that it had paid down about $1.1 billion in secured term loans and now seeks to refinance and amend its existing credit agreement, borrow more money under the agreement, and issue new secured debt. Investors can’t hit the exits fast enough.

Hot Oil Stocks To Buy For 2018

European stocks ended a choppy session firmly lower on Tuesday, as a renewed slump in oil prices drove energy shares lower.

The Stoxx Europe 600
SXXP, +0.69%
dropped 1% to close at 338.72 after rising as much as 0.6% in early trade. The oil and gas sector
SXEP, +0.85%
was putting in the worst performance as it lost 2.8%.

Hot Oil Stocks To Buy For 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Virendra Singh Chauhan]

    Nvidia corporation stock shook off the bad performance from the last week, with a nearly 3% gain in the first trading session of this week. If you are wondering whether or not NVIDIA stock has turned the corner, a recent tweet from NVIDIA bear Andrew Left offers some answers. In late December, Citron’s Andrew Left issued a bearish NVDA call, calling a $90 bottom on the stock. Well, the famed short seller of Valeant (NYSE:VRX) fame, recently disclosed that he had covered its short position on NVIDIA. Given that Citron had originally called for a $90 price target, it appears likely that Citron thinks NVDA stock has bottomed out $10 above its original target.

  • [By Stark Merrifield]

    Bill Ackman: Fifty-year-old Ackmans career began in 1992 when he and fellow Harvard graduate David P. Berkowtiz founded the investment firm Gotham Partners. The firms high-profile bid for Rockefeller Center in New York caused investors to flock to the firm, growing it to $500 million in assets. Then in 2004, with $54 million in personal funding, Ackman started Pershing Square Capital Management. Through Pershing, Ackman bought significant shares in companies like Wendys Co. (Nasdaq: WEN), Target Corp. (NYSE: TGT), Chipotle Mexican Grill Inc. (NYSE: CMG), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). Today, Ackman is worth $1.4 billion and is No. 256 on the Forbes 400.

  • [By Sreekanth Anasa]

    Can Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock rise further after the recent pop?

    Shares ofCanada based specialty pharma company Valeant Pharmaceuticals Intl Inc (NYSE:VRX) registered a double-digitpop in the last trading session, Friday, December 8th. However, there was no obvious catalyst for the recent gains. The 11% pop could have been on account of carryover news and a general move higher in the broader market. Now, after the latest pop, investors would be wondering, can VRX stock continue to rise further from here? Will the rally in Valeant stock continue?The answer to this could be partly found in the VRX stock technical chart.

Hot Oil Stocks To Buy For 2018: Christopher & Banks Corporation(CBK)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Christopher & Banks Corporation (NYSE: CBK) got a boost, shooting up 24 percent to $1.50 after the company reported strong preliminary revenue for the third quarter.

  • [By Lisa Levin]

    Christopher & Banks Corporation (NYSE: CBK) shares were also up, gaining 40 percent to $2.64. Christopher & Banks reported a Q4 loss of $0.24 per share on revenue of $94.6 million. The company projects Q1 revenue of $93 million to $98 million.

Hot Oil Stocks To Buy For 2018: HealthEquity, Inc.(HQY)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

investment trading

To understand Aflac (NYSE:AFL), the first thing you have to realize is that the company does much more than just offer supplemental insurance in the U.S. market. Aflac’s primary business is in Japan, where it serves a larger market and produces more of its revenue and profit than its domestic operations do. Coming into Tuesday’s fourth-quarter financial report, Aflac investors wanted to see continuing signs of solid growth in revenue and earnings, but the insurer didn’t produce the growth in operating earnings that it had hoped to achieve. Let’s look more closely at Aflac to see what its results say about the company going forward.

Image source: Aflac.

Aflac posts mixed results

Aflac’s fourth-quarter results showed the impact of the different conditions the insurer faces in its worldwide operations. Total revenue jumped 12% to $5.96 billion, which was nearly double the growth rate that most investors were expecting to see in Aflac’s top line. Net earnings, however, were up only 3% from year-ago levels. Using Aflac’s favored operating earnings measure and adjusting for currency impacts, the insurer’s bottom-line figure of $1.46 per share was $0.17 less than the consensus forecast among those following the stock.

investment trading: Ryder System Inc.(R)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Ryder System (R) tumbled to the bottom of the S&P 500 today after it missed earnings forecasts and cut its full-year guidance.

    Getty Images

    Ryder Systemdropped 14% to $68.28 today, while the S&P 500 0.6% to 2,388.61

    Ryder Systems reported a profit of 82 cents a share, missing forecasts for 84 cents, on sales of $1.75 billion, ahead of forecasts for $1.7 billion. Ryder cut its 2017 guidance to a range of $4.25 to $4.55, below the Street consensus for $5.17.

    Ryder System’s market capitalization fell to $3.7 billion today from $4.2 billion yesterday.

investment trading: Multi Packaging Solutions International Limited(MPSX)

Advisors’ Opinion:

  • [By Bradley Seth McNew]

    Multi Packaging Solutions International Ltd. (NYSE:MPSX) shares jumped 23% as of noon EST today, on the news that the packaging company would be acquired by WestRock Company (NYSE:WRK) in a deal worth $2.3 billion, including nearly $900 million of debt.

investment trading: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Sean Williams]

    Shares of Valeant Pharmaceuticals (NYSE:VRX), an embattled drug developer whose primary method of growth over the past couple of years has been via acquisitions and price hikes on its therapies, surged as much as 15% on Thursday for their third consecutive day of strong gains. The stock was up a more modest 9% as of the closing bell.

  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) second-quarter results also are scheduled for Tuesday. The consensus forecast is $2.24 billion in revenue and earnings per share (EPS) of $0.97. Shares were last seen at $15.13. The 52-week range is $8.31 to $32.74.

  • [By Kumar Abhishek]

    Source:Micron Technology Inc Technical Charts by amigobulls.com

    Valeant Pharmaceuticals Intl Inc (NASDAQ:VRX) stock facing resistance.

    Shares of specialty pharma company Valeant Pharmaceuticals Intl Inc (NYSE:VRX)are in a downtrend for more than two months now. Valeant Pharmaceuticals Intl Inc stock was down by almost 50% since its Q1 2017 earnings at the end of February. The stock had made a new 52-week low at $8.36 a week back. Since then the stock has been able to make a marginal recovery, gaining more than 10% this week. However, the stock is now facing resistance from its 20-day moving average. Valeant stock had been unable to break out above the resistance line in the past and had continued to slide downwards. The stock is again likely to face strong resistance from the 20-day moving average. The declining volumes over the week indicate that the stock will find it tough to make a bullish crossover, over the 20-day moving average.

investment trading: The NeutriSci International (NU)

Advisors’ Opinion:

  • [By Matthew Briar]

    Last week — to the day, in fact — Lexaria Bioscience Corp (OTCMKTS:LXRP) announced it was teaming up with neutraceutical company NeutriSci International Inc (CVE:NU) to create a new kind of health supplement that gave consumers the ability to tap into the benefits of hemp. We hailed it as the shape of things to come. What we didn’t know, however, was how quickly those things would take shape. Just this morning the company told LXRP shareholders it was already forging another such symbiotic relationship…. this one with Hempco Food and Fiber Inc (CVE:HEMP).

    Simply put, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.

    It’s not widely recognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity. Hemp, and hemp oil to be exact, can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.

    The future for Lexaria Bioscience is partnerships… licensing its science and know-how to companies with existing product lines and distribution networks that can easily inject hemp

  • [By Matthew Briar]

    What do you get when you cross a science that drastically improves the absorption of cannabidiol (the healthy component of cannabis) with pterostilbene (an antioxidant) tablet? It’s not a joke in search of a punch line. It’s going to be the health supplement millions of consumers have been waiting for, brought to them by a joint venture between NeutriSci International Inc (CVE:NU) and Lexaria Bioscience Corp (OTCMKTS:LXRP). The two companies announced this morning they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line.

    Lexaria has developed and patented a technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.

    Just to be clear, hemp and marijuana are not the same thing. Hemp doesn’t have any tetrahydrocannabinol (or THC) in it, which is the key driver of its psychoactive — the ‘high’ — response. Hemp, and hemp oil to be exact, does have cannabidiol in it though, and for those who’ve been following the saga of medical marijuana and cannabis, they’ll know cannabidiol can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.

    NeutriSci International is Canadian corporation that specializes in the marketing, development and distribution of proprietary nutraceuticals. It’s got a rather wide array of products in its portfolio, but the one of immediate interest is its pterostilbene, as it fits best with the hemp-absorption technology Lexaria Bioscience brings to the table.

    Pterostilbene (found in blueberries, by the way) is o

  • [By Bryan Murphy]

    In the grand scheme of things it shouldn’t be surprising, though odds are good at least a few people are surprised at how quickly it happened. That is, health supplement and healthy-foods brand name NeutriSci International Inc (CVE:NU) and the developer of a cannabis-infusion technology — a means of packing more CBD into hemp oil — called Lexaria Bioscience Corp (OTCMKTS:LXRP) have finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.

    The benefits of cannabidiol, found in hemp and marijuana, are relatively well understood by the market at this point. Cannabidiol can do a human body a lot of good, like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more. Pterostilbene is the lesser-known of the two components of the new tablet, but no less impressive and no less beneficial. Pterostilbene is known to combat high cholesterol, high blood pressure, and oxidative stress. Combining the two is a real one-two punch for the health-conscious.

    That’s what made November’s news so exciting… NeutriSci International has an established name and marketing channel, while Lexaria Bioscience has the science that makes hemp oil far more functional. Indeed, to fully appreciate the upside for LXRP, one has to embrace Lexaria’s science and why it matters.

    The bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short,

  • [By Matthew Briar]

    Indeed, it’s also garnered interest from business partners. In November, Lexaria Bioscience and NeutriSci International Inc (CVE:NU) jointly announced they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line. In January, the duo announced it had finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.

investment trading: EQT Midstream Partners, LP(EQM)

Advisors’ Opinion:

  • [By WWW.INVESTOPEDIA.COM]

    Companies in the oil storage business can take advantage of what is known as contango, which is when forward prices are higher than current prices, allowing the purchase of cheap oil to be stored and sold at a later date while securing income using derivatives. Five companies that appear to be in a good position to take advantage of reduced oil storage capacity are Magellan Midstream Partners (NYSE: MMP), Enterprise Products Partners (NYSE: EDP), Spectra Energy Partners (NYSE: SEP), Buckeye Partners (NYSE: BPL) and EQT Midstream Partners (NYSE: EQM).

  • [By Elizabeth Balboa]

    Not only does Jana consider the deal price overvalued, but it looks to redirect EQT’s focus to a breakup of pipeline operations to transform the core company into an exploration & production firm. The pipelines already trade publicly under EQT Midstream Partners LP (NYSE: EQM) and EQT GP Holdings LP (NYSE: EQGP).

Top 10 Canadian Stocks To Watch For 2018

In the endless flow of millennial-focused surveys, one finally stuck out to me.

It came via email from Canadian firm RBC Wealth Management, which found that when it comes to money, millennials are more confident and prepared than previous generations. We feel responsible for understanding our financial affairs and do research to improve our financial knowledge, the survey reported.

I believe all of this is true, which is why I initially overlooked that this survey wasn’t actually about a group to which I belong: It was solely focused on high net worth millennials, specifically 479 respondents under age 35 with average investable assets of $5.7 million. The majority in this group expect to receive an inheritance, if they haven’t already.

Credit: Shutterstock

So: Rich millennials with rich parents are doing great — financially speaking, anyway. What about the rest of us?

Top 10 Canadian Stocks To Watch For 2018: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

Top 10 Canadian Stocks To Watch For 2018: PPL Corporation(PPL)

Advisors’ Opinion:

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $31.53 after closing Tuesday at $32.42. The 52-week high is $40.20. Volume was about 15.5 million, more than three times the daily average of around 4 million shares. The electric utility company took a downgrade on Tuesday and the fallout continues to drop.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $31.11 after closing Wednesday at $31.59. The 52-week high is $40.20. Volume was about 9.6 million, more than double the daily average of around 4.2 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $30.81 after closing Friday at $31.13. The 52-week high is $40.20. Volume was about 3.5 million, about 25% below the daily average of around 4.5 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $32.48 after closing Monday at $33.97. The 52-week high is $40.20. Volume was about 5.9 million, nearly a third higher than the daily average of around 3.9 million shares. The electric utility company had no specific news.

Top 10 Canadian Stocks To Watch For 2018: Rhino Resource Partners LP(RNO)

Advisors’ Opinion:

  • [By Alexis Xydias]

    Investors are regaining confidence, squeezing pessimists who say the economy remains sluggish outside of Germany and point to record-low trading volume as a lack of conviction in the Euro Stoxxs 61 percent rally of the past two years. Besides gains in stocks from Banco Bilbao Vizcaya Argentaria SA to Renault SA (RNO), yields on Spanish and Italian bonds have declined to a two-year low compared with German bunds and the euro has strengthened 4.6 percent to $1.35 in the past six months.

Top 10 Canadian Stocks To Watch For 2018: Thor Industries Inc.(THO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Thor Industries, Inc. (NYSE: THO) got a boost, shooting up 14 percent to $102.70 as the company reported stronger-than-expected results for its first quarter on Monday.

  • [By Peter Graham]

    A long term performance chart shows shares of Winnebago Industriesalong withmid cap peers Thor Industries, Inc (NYSE: THO) and LCI Industries (NYSE: LCII) all giving a very similar performance and largely taking off starting in 2016:

  • [By Peter Graham]

    A long term performance chart shows shares of Winnebago Industries and small cap peer Thor Industries, Inc (NYSE: THO) giving a similar performance with shares taking off last year before stumbling this year while Drew Industries, Inc (NYSE: DW) has mostly underperformed:

  • [By WWW.THESTREET.COM]

    In his second “Executive Decision” segment, Cramer spoke with Bob Martin, president and CEO of Thor Industries (THO) , a stock that was crushed today, down 9.8%, on a penny-a-share earnings beat with tempered guidance.

Top 10 Canadian Stocks To Watch For 2018: NRG Energy Inc.(NRG)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was NRG Energy, Inc. (NYSE: NRG) which rose over 5% to $22.20. The stocks 52-week range is $9.84 to $23.36. Volume was over 35 million compared to its average volume of 5.8 million.

  • [By Ben Levisohn]

    NRG Energy (NRG) has gained 2.1% to $18.49 after getting raise to Buy from Neutral at Goldman Sachs.

    Skechers USA (SKX) has tumbled 5.4% to$28.35 after getting cut to Negative from Positive at Susquehanna.

  • [By Craig Jones]

    Pete Najarian said that there was a big options activity in NRG Energy Inc (NYSE: NRG). Traders were aggressively buying the October 26 calls. Around 6,000 contracts were traded in the first half of the session and they were paying 65 cents for them. The trade breaks even at $26.65 or more than 11 percent above the current market price.

  • [By Lisa Levin]

    In trading on Wednesday, utilities shares fell 0.25 percent. Meanwhile, top losers in the sector included NRG Energy Inc (NYSE: NRG), down 3 percent, and Entergy Corporation (NYSE: ETR) down 1 percent.

  • [By Lisa Levin]

    Non-cyclical consumer goods & services sector was the top gainer in the US market on Wednesday. Top gainers in the sector included Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG), Companhia Paranaense de Energia (ADR) (NYSE: ELP), and NRG Energy Inc (NYSE: NRG).

Top 10 Canadian Stocks To Watch For 2018: 3M Company(MMM)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Who are the likely candidates for the next round of upgrades? Cramer said he’s betting that 3M (MMM) will be in the mix, along with Walmart (WMT) and especially Home Depot (HD) , which should have a strong spring planting season with good comparisons to last year. Investors might also see upgrades on Honeywell (HON) and Nike (NKE) , Cramer suggested.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded down 1.69% at $230.78. The stock’s 52-week range is $163.85 to $238.90. Volume was about equal to the daily average of around 1.7 million. The company had no specific news Monday.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded down 1.05% at $210.38. The stock’s 52-week range is $163.85 to $214.57. Volume was about 20% below the daily average of around 1.8 million. The company had no specific news.

Top 10 Canadian Stocks To Watch For 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    2017 has turned out to be a good year for Valeant Pharmaceuticals Intl Inc(NYSE:VRX) so far. Shares of thespecialty pharma company have been on atear of late. Valeant stock has gained more than 25% since the end of January compared to over 3% gain in Nasdaq Composite (INDX:COMPX). The stock has gained more than 10% in the last two days. Valeant stock is up another 5% in the pre-market trade today on the news that FDA has approved “Siliq” (orbrodalumab as it was previously known), a drug marketed by Valeant to treat adults with moderate-to-severe plaque psoriasis.

  • [By Ben Levisohn]

    If it feels like it’s been all Valeant Pharmaceuticals International (VRX) today, I get it, and I promise this will be my last post on the company today. But really, how often do we get to see a fund manager acknowledge a spectacular mistake in such publicfashion?

    Photo: Andrew Harrer/Bloomberg

    As if it weren’t obvious yet, Ackman’s exit is bad news for the stock.Yes, some analysts have tried to focus on other issues that could be positive, but, really, as long as Ackman was around, you knew someone big had Valeant’s back. And now he’s gone. We at Barron’s were never too enthusiastic about Valeant–Vito Racanelliwrote bearishly on the company 2014–or Ackman’s involvement. But it he was your reason to be in Valeant, well consider what Wells Fargo analyst David Maris has to say:

    …we believe investors will take Pershing Squares exit as a reflection that 1) the outlook is negative; 2) the potential for meaningful near-term asset sales is unlikely; 3) the legal proceedings/investigations may have greater risk than the Street is appreciating; 4) a turnaround will take longer than expected or is not possible; and 5) the debtholders have an advantaged position in the capital structure, and as such the equity holders are at their mercy, especially in a bankruptcy situation. We believe investors would consider this as a sign that the next several years may not represent a major turnaround for the company.

    Shares of Valeant have dropped 11% to$10.76 at 3:12 p.m.

  • [By Kumar Abhishek]

    Valeant Pharmaceuticals Intl Inc(NYSE:VRX) stock has been rallying going into this earningsseason. Valeant stock is up by more than 20% since the beginningof February. VRX stock is currently facing resistance from the100-day simple moving average trendline. The run in the stock has been driven by the FDA approval of “Saliq”, a drug marketed by Valeant to treat adults with moderate-to-severe plaque psoriasis, and the company’s asset sales plans. Valeant has announcedasset sales of more than $2.5 billion since the beginning of the year. These asset sales will help in paring down some portion of Valeant’s $30 billion debt which is holding down the stock.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 2.4% Monday to post a new 52-week low of $8.31 after closing Friday at $8.51. The stock’s 52-week high is $38.50. Volume of around 13.5 million shares was about 65% below the daily average of around 18.8 million. The company had no specific news, and shares are on track to add about 1.5% by the closing bell.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 2.7% Tuesday, to post a new 52-week low of $10.35 after closing at $10.64 on Monday. The stock’s 52-week high is $38.50. Volume was nearly equal to the daily average of around 18.6 million shares. The battered drug maker completed a $1.1 billion bond tender offer as investors couldn’t wait to cash out.

Top 10 Canadian Stocks To Watch For 2018: Plains All American Pipeline L.P.(PAA)

Advisors’ Opinion:

  • [By Dustin Parrett]

    Plains All American Pipeline (NYSE: PAA) controls 4 million barrels of crude oil and natural gas a day.

    And with higher oil prices and fewer restrictions leading to more drilling, PAA’s pipelines will be in demand in 2017.

  • [By Dustin Parrett]

    We think Plains All American Pipeline L.P. (NYSE: PAA) is one of the best oil stocks to buy this year. In fact, we see a scenario where PAA stock could jump 20% in 2017.

  • [By Matthew DiLallo]

    One of the largest projects is the Saddlehorn Pipeline, which Magellan is building with Plains All American Pipeline (NYSE:PAA) and Anadarko Petroleum (NYSE:APC). Both Plains All American Pipeline and Magellan own 40% of the project, which puts their total investment at $230 million apiece. They expect the project to be fully operational early next year, which is noteworthy given its robust first-year economics. Magellan estimates that it will earn eight times EBITDA on the capital deployed, or roughly $28.8 million in annual EBITDA apiece for Magellan and Plains All American Pipeline on their investment.

Top 10 Canadian Stocks To Watch For 2018: Transcananda Pipelines Ltd.(TRP)

Advisors’ Opinion:

  • [By WWW.KIPLINGER.COM]

    Energy stocks were driven by a hefty dose of M&A during the third quarter. And that will drive returns for TransCanada Corporation (TRP) during the next one.

  • [By Ben Levisohn]

    In a number of articles recently, following the US recent revival and potential approval of the previously blocked Keystone XL pipeline, a number of estimates have been provided suggesting a pending boom for the US steel industry is on the horizon (and US steel stocks have reacted in kind). In fact, this optimism, we believe, peaked today when a report from one of our competitors was published claiming that, the keystone XL pipeline could increase line pipe demand by 14.7% for 2 years. The problem here, we believe, rests with the facts that: (a) TransCanada (TRP) has already taken, and paid for, the steel to build the Keystone XL pipeline (the steel currently sits in storage facilities in both Regina, Canada and Arkansas, United States), (b) neither US Steel (X; SELL), AK Steel, Steel Dynamics, or Nucor have the ability to make the specialized steel required for the miles of pipe associated with this project, to include both the thickness and pressure requirements, according to this article from Reuters, and (c) assuming some of the pipe does need replacement, this would likely come from international steel makers who are capable of producing the specialized steel (again, as highlighted in this Reuters article).

  • [By Matthew DiLallo]

    After a series of setbacks in its attempts to build new oil pipelines, Canadian pipeline giant TransCanada (NYSE:TRP) completed a transformation transaction to acquire U.S. natural gas pipeline company Columbia Pipeline Group for $13 billion, which includes the assumption of debt. The key to that deal was that it increased the combined company’s near-term project pipeline to 23 billion Canadian dollars, which supports TransCanada’s ability to increase its dividend by 8% to 10% annually through 2020. After completing that deal, TransCanada made a bid to acquire all of the outstanding units that it did not own of affiliated MLP Columbia Pipeline Partners (NYSE:CPPL) in a transaction valued at $915 million. These acquisitions solidified TransCanada’s natural gas pipeline growth ambitions, enabling it to diversify away from oil pipelines.

  • [By Paul Ausick]

    That includes pipeline companies like Kinder Morgan Inc. (NYSE: KMI), which already operates a pipeline transporting natural gas from Texas into Mexico, and master limited partnerships (MLPs) Energy Transfer Partners L.P. (NYSE: ETP) and TransCanada Corp. (NYSE: TRP), the company that has (so far) failed to get U.S. approval for its Keystone Pipeline expansion from Canada’s oil sands across the U.S. border.

Top 10 Canadian Stocks To Watch For 2018: NEW GOLD INC.(NGD)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market lost ground on Monday, sending major market benchmarks lower by more than half a percentage point. The Dow lost its grip on the 20,000 mark in the wake of concerns about economic growth and new U.S. immigration policy, and some believe that the broader geopolitical climate could have a negative impact on global commerce that in turn could start affecting multinational corporations’ business prospects. In addition, bad news from some individual companies weighed on the markets, and Transocean (NYSE:RIG), Rite Aid (NYSE:RAD), and New Gold (NYSEMKT:NGD) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top Canadian Stocks To Buy For 2018

Introduction – Railroads as an Investment Option

Railroads – many of us cross over tracks everyday on our commute to work each day and some of us actually taking a train on a daily basis perhaps. Railroads have been around for a long time, moving all sorts of cargo from coast to coast. Railroad stocks took it on the chin not too long ago due to coal weakening and oil production being cut in conjunction with increased utilization of pipelines to transport gas and oil, but public railroad stocks can be an exceptional investment option in a growing economy as they move many materials and goods. They may not be an exciting investment but they sure can be effective – take a look at the chart below. Over the past five years, Union Pacific Corporation (NYSE:UNP), CSX Corporation (NYSE:CSX), and Canadian National Railway Company (NYSE:CNI) have all outperformed the S&P by as much as 58%.

Top Canadian Stocks To Buy For 2018: ConocoPhillips(COP)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Phillips 66 is a multi-national company headquartered in Westchase, Houston. It was spun off from ConocoPhillips (NYSE: COP) in 1917.

    Stock Return (Since 2012): 144.1 percent.

  • [By WWW.THESTREET.COM]

    The contract awards are for the jack-ups West Elara and West Linus with ConocoPhillips Skandinavia AS (COP) for work in the Greater Ekofisk area. The total additional backlog for the new contract awards is estimated to be about $1.4 billion, excluding performance bonuses.

  • [By WWW.THESTREET.COM]

    ConocoPhillips (COP) was upgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: COP.

    Urban Outfitters (URBN) was downgraded to market perform at William Blair. Continued comp-store sales pressure is pushing out the timeline for a potential recovery, Blair said. 

  • [By Dustin Parrett]

    Big Oil stocks are the seven “oil supermajors” that do everything from oil drilling to refining to retail sales. This is a list of the Big Oil companies:

    Big Oil CompanyShare PriceYTDMarket CapExxon Mobil Corp. (NYSE: XOM)$83.44-7.58%$353.13BChevron Co. (NYSE: CVX)$113.56-3.5%$217.62BConocoPhillips Co. (NYSE: COP)$48.21-3.78%$61.42BRoyal Dutch Shell Plc. (NYSE ADR: RDS.A)$52.35-3.82%$221.08BBP Plc. (NYSE ADR: BP)$34.12-8.71%$112.69BTotal SA (NYSE: TOT)$50.26-1.35%$124.6BEni SpA (NYSE: E)$31.51-2.3%$58.69B

    Despite being huge global oil companies, shares of Big Oil stocks are all in the red this year. Those losses have all happened even as the Dow is smashing record highs and trading up 6.4% year to date.

  • [By WWW.KIPLINGER.COM]

    Spun off from energy producer ConocoPhillips (COP) a few years back, PSX has quickly become one of the downstream industrys biggest players. Refiners earn profits based on the difference between feed stock costs (Think oil and natural gas prices) and the price for refined products such as gasoline, jet fuel and heating oil. Those inputs remain low, and Phillips 66 is minting cash as a result.

Top Canadian Stocks To Buy For 2018: Wells Fargo & Company(WFC)

Advisors’ Opinion:

  • [By WWW.KIPLINGER.COM]

    Cliches aside, Wells Fargo & Co. (WFC) might not be the most popular name after its phony accounts scandal, but so what? Its still a quality business with a quality stock that yields 3.4%.

  • [By JPMorgan]

    We recommend Wells Fargo into 2016 for several reasons: 1) a safe haven stock in a choppy, uncertain time period; 2) some benefit from acquisitions from GE Capital; 3) continued growth in several other areas – investment banking, credit cards, and payments; and 4) continued sizable capital return. 

  • [By Chris Dier-Scalise]

    Among the brands being sold were Alcoa Corporation (NYSE: AA) and Ford Motor Company(NYSE: F), which both paid out dividends in December. The financial and oil sectors also experienced a sell-off to finish 2016. Wells Fargo & Co (NYSE: WFC) and Citigroup Inc (NYSE: C) were net sold as each reached new year-to-date highs and investors unloaded ConocoPhillips (NYSE: COP) and Chevron Corporation (NYSE: CVX) as their prices normalized with the rise in the price of oil.

  • [By Ben Levisohn]

    Big banks like JPMorgan Chase (JPM), Wells Fargo (WFC), and Bank of America (BAC) have surged more than 20% during the past three months–causing many investors to doubt the possibility for further gains. I’m note one of them–after my disastrous financials call last year, I’m bullish on them in 2017–and neither is Morgan Stanley’s Betsy Graseck, who remains Overweight the big banks, despite their big gains. She explains why:

  • [By Ben Levisohn]

    Bank stocks have had quite a run since Donald Trump’s 2016 presidential election victory–such a run, in fact that Baird’s David George and team worry that most of the benefits of “potential improvement in macro growth, regulatory relief, and corporate tax reform” seem priced into their stocks. They recommend investors “selectively reduce bank exposure” but still like Wells Fargo (WFC), which they call a “top buy idea.” They explain why:

Top Canadian Stocks To Buy For 2018: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

Top Canadian Stocks To Buy For 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    Shares of specialty pharma company Valeant Pharmaceuticals Intl Inc(NYSE:VRX)have tanked more than 20% in last two trading sessions, breaching the support from the 50 day SMA, after the Laval,Quebec-based company reported its Q4 and FY 2016 earnings on Tuesday, before the market opened. While the earnings itself were better than expected, the guidance for FY 2017 didn’t go down well with investors and wall street, earning the company multiple price target cuts. Valeant reported an adjusted profit of $1.26 a share against analysts’ estimateof $1.21. This was Valeant’s first beat in a long time. Even on the revenue front, the company reported better than expected results. Initially, the stock gained on the report of an earnings beat. However, once the guidance figures came in, the stock tanked. In our earnings preview of Valeant, we had said that the adjusted EBITDA guidance for 2017 will be the key driver of VRX stock after the earnings.

  • [By Benzinga News Desk]

    Just days after Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares took a steep tumble below the $11 level, the stock is almost back to an important level at $12: Link

  • [By Ashley Moore]

    The current rally of Valeant Pharmaceuticals International Inc. (NYSE: VRX) is being driven by two things. While investors are viewing these two catalysts as bullish, they are really just temporary solutions.

  • [By Casey Wilson]

    As disgraceful as Mylan’s pricing strategy may be, this next pharmaceutical firm is hated even more – and makes our list for the second year in a row…

    Most-Hated Companies 2016 No. 1: Valeant Pharmaceuticals International Inc. (NYSE: VRX)

    The troubled pharmaceutical company is deeply loathed by both consumers and investors alike.

Top 5 Canadian Stocks To Invest In Right Now

Canadian Prime Minister Justin Trudeau promised he would implement massive changes to Canada marijuana laws. And when he does, it will create a new and booming economy.

If Canada places a “sin tax” of 50% on recreational marijuana sales, the country could make $5 billion annually, according to a CIBC World Markets report.

Currently, only medical marijuana is legal in Canada.

But an overwhelming amount of Canadians support legalizing recreational marijuana…

According to a poll conducted in the summer of 2016, 43% of the 1,000 Canadians surveyed supported legalizing recreational marijuana. Also, 26% of those surveyed somewhat supported legalizing recreational marijuana.

Only 17% were opposed, and 9% were somewhat opposed.

Top 5 Canadian Stocks To Invest In Right Now: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

Top 5 Canadian Stocks To Invest In Right Now: NEW GOLD INC.(NGD)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market lost ground on Monday, sending major market benchmarks lower by more than half a percentage point. The Dow lost its grip on the 20,000 mark in the wake of concerns about economic growth and new U.S. immigration policy, and some believe that the broader geopolitical climate could have a negative impact on global commerce that in turn could start affecting multinational corporations’ business prospects. In addition, bad news from some individual companies weighed on the markets, and Transocean (NYSE:RIG), Rite Aid (NYSE:RAD), and New Gold (NYSEMKT:NGD) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top 5 Canadian Stocks To Invest In Right Now: Encana Corporation(ECA)

Advisors’ Opinion:

  • [By Money Morning News Team]

    Canada-based Encana Corp. (NYSE: ECA) was the eighth top oil company stock in 2016, with a 131% gain over the year. ECA and its subsidiaries focus on developing, exploring, producing, and marketing natural gas, liquefied natural gas, and oil in North America.

  • [By Paul Ausick]

    Encana Corp. (NYSE: ECA) is rated Buy with an unchanged price target of $16. The EPS estimate for 2017 was lowered from $0.42 to $0.34, and the 2018 estimate was also lowered, from $1.47 to $1.28. The shares ended the weekat $11.44, in a 52-week range of $4.90 to $13.85. The consensus 12-month price target is $14.95.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Vodafone Group (VOD) , Schlumberger (SLB) , Encana (ECA) , Arconic (ARNC) and AdvanSix (ASIX) .

    Cramer was bearish on U.S. Silica Holdings (SLCA) .

Top 5 Canadian Stocks To Invest In Right Now: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
    Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today!   Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.

  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) second-quarter results also are scheduled for Tuesday. The consensus forecast is $2.24 billion in revenue and earnings per share (EPS) of $0.97. Shares were last seen at $15.13. The 52-week range is $8.31 to $32.74.

  • [By Lisa Levin]

    Healthcare shares rose by 1.68 percent in the US market on Thursday. Top gainers in the sector included Sangamo Therapeutics Inc (NASDAQ: SGMO), Valeant Pharmaceuticals Intl Inc (NYSE: VRX), and Tenet Healthcare Corp (NYSE: THC).

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 2.7% Tuesday, to post a new 52-week low of $10.35 after closing at $10.64 on Monday. The stock’s 52-week high is $38.50. Volume was nearly equal to the daily average of around 18.6 million shares. The battered drug maker completed a $1.1 billion bond tender offer as investors couldn’t wait to cash out.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 2% Friday to post a new 52-week low of $9.44 after closing Thursday at $9.63. The stock’s 52-week high is $38.50. Volume of nearly 15 million shares was about 25% below the daily average of around 19.5 million. The stock is on track to post a gain of around 0.5% for the day following an offer from Fresenius SE to acquire Akorn. Barron’s suggests that investors must believe there’s a buyer for anything, so why not Valeant?

Top 5 Canadian Stocks To Invest In Right Now: Prestige Brand Holdings Inc.(PBH)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Castor believes the cash has disappeared into working capital, which has grown from 23% to more than 50% since 2008. Comparable company PrestigeBrand (PBH) uses 11%; Unilever(UL) and Colgate-Palmolive(CL) far less.